Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose-ranging study of efavaleukin alfa in systemic lupus erythematosus
2020-003509-72Phase 2Completed
- Sponsor
- Amgen
- Start
- Mar 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Efavaleukin alfa (dose-ranging) with Placebo + standard of care (2 arms). Primary endpoint: SRI-4 response at week 52. Started Mar 2021; status: completed.
02
Drugs
efavaleukin alfa
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2020-003509-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003509-72.